| Budget Amount *help |
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
The role of phosphorylated-RXRa (p-RXRa) on the development of liver tumorigenesis was investigated by using RXRa genetically modified mice. The transgenic mice were more susceptible to the treatment of diethylnitrosamine (DEN), and developed more liver tumors compared to the control mice. In addition, liver tumors observed in the transgenic mice had more PCNA positive cells, indicating that those tumors had high proliferative capacity. Besides, increased mRNA and protein expressions of cyclin D1 were observed in transgenic liver tumors, and the protein expressions of either p-Rb or PCNA, both of which are the downstream targets of cyclin D1, were also increased in those liver tumors. Interestingly, the transgenic liver tumors had more b-catenin protein expression, which regulates the expression of cyclin D1. Thus, these results indicate that the p-RXRa is associated with the development of DEN-induced liver tumorigenesis by promoting b-catenin/cyclin D1 signaling pathway.
|
